Alerta

SYSTEM FOR CARGO TRANSPORT

Resumen de: AU2022471272A1

A system for cargo transport in the field of intermodal logistics aims to solve supply chain-related disruptions experienced during the Covid-19 pandemic. Cargo frame cargo ships (24), cargo frame barges (26), cargo frame docks (20), 3-axis structures, and 3-axis hoists (10) utilize a cargo frame to bundle series 1 freight containers, vehicles, dry-bulk, wet-bulk, and other general cargoes in a stackable, modular manner. Purpose-built 3-axis structures increase the footprint of ports where cargo frames are stacked, stored, and retrieved. Semi-truck queueing towers (22), and freight car transshipment yards (34) allow for timely coordination of cargo transfer at a multi-level port (48), increasing the throughput of intermodal cargoes.

REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION

Resumen de: US2025082716A1

Provided are methods for treating subjects with coronavirus infections. The methods include providing a subject infected with a coronavirus resulting in a prothrombotic condition in addition to being infected by a coronavirus, and administering to the subject an angiotensin (1-7) peptide or an analog or derivative thereof, a Mas Receptor (MasR) agonist, or any combination thereof. The subject may be suffering from COVID-19 disease, including but not limited to a thrombotic complication, an adverse pregnancy outcome, and/or a complication resulting from an underlying prothrombotic state. Also provided are compositions that include Ang (1-7) peptides, analogs, and/or derivatives thereof that are associated with degradable and/or non-degradable polymers having electrostatic interactions therewith, hydrophobic interaction therewith, hydrogen bonding interactions therewith, or any combination thereof. Also provided are uses of Ang (1-7) peptides, analogs, and/or derivatives thereof and/or a Mas Receptor (MasR) agonists for treating subjects infected with coronaviruses and/or for preparing medicaments therefore.

CIRCULAR RNA VACCINES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF

Resumen de: US2025082746A1

Provided are circular RNAs (circRNAs) encoding an antigenic polypeptide of a SARS-CoV-2 variant. Provided are circRNA vaccines against a SARS-CoV-2 variant, such as a Delta or Omicron variant. The circRNA vaccine comprises a circRNA comprising a nucleic acid sequence encoding an antigenic polypeptide comprising a Spike(S) protein or a fragment thereof of a SRAS-CoV-2 variant. Also provided are methods of treating or preventing a SARS-CoV-2 infection using the circRNAs or compositions thereof.

NEBULIZER CUP AND USE THEREOF IN NEBULIZATION INHALATION ADMINISTRATION

Resumen de: US2025082869A1

Disclosed are a nebulization cup and application in nebulized inhalation administration thereof, and especially application in nebulized inhalation administration of a preventive and/or therapeutic drug for a respiratory disease (such as SARS-CoV-2 vaccine). After adding an antistatic agent, the nebulization cup can effectively maintain the stability of drug mist within a certain period of time, with stable particle size, less drug residue in the cup, thus ensuring effective inhalable amount, and the administration operation is simple and convenient, thus the nebulization cup can significantly improve the inoculation efficiency and can be used for large-scale inoculation.

ACE2 FUSION PROTEINS AND USES THEREOF

Resumen de: US2025082737A1

The present invention relates to fusion proteins of ACE2 with IgM or IgG2 Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.

LIFE WAVES FOR THERAPY AND USES THEREOF

Resumen de: US2025082541A1

The present invention provides an acumoxa therapy device utilizing energy waves for preventing, alleviating or treating COVID-19 (SARS-COV-2) coronavirus infection. In one embodiment, the device delivers energy in a non-invasive manner. In one embodiment, the device is configured to include an energy pin and one or more energy rings. In one embodiment, the device delivers sufficient energy to certain body parts such as acupoints to achieve an intervening and/or. therapeutic effect. In one embodiment, the device can maintain or improve general health, or can alleviate or treat a subject with COVID-19 infection and one or more other conditions. In one embodiment, the present invention also discloses a system comprising the device and uses thereof.

COMPOUNDS FOR TREATMENT OF INFLAMMATORY PROCESSES

Resumen de: AU2023346793A1

The present disclosure relates to the use of compounds such as compounds of Formula (I) or a pharmaceutically acceptable salt, solvate and/or prodrug thereof, for example, in pharmaceutical compositions and in the treatment of diseases, disorders or conditions such as diseases, disorders or conditions treatable by inhibiting SWAP-70 and/or treatable by inhibiting neutrophil reactive oxygen species (ROS) production, neutrophil NETosis, B lymphocyte plasmablast development, B lymphocyte IgE production, mast cell degranulation, eosinophil ROS production, mast cell cytokine release, B lymphocyte cytokine release, endothelial cell cytokine release, endothelial cell-immune cell interactions, and/or macrophage/monocyte migration, such as treatment of lung inflammation induced by viruses such as SARS-CoV-2.

METHOD FOR DETECTING ANTI-SARS-COV-2 SPIKE (S) IMMUNOGLOBULINS

Resumen de: US2025085282A1

Disclosed are methods for detecting if a biological sample (e.g., serum, blood, plasma) contains antibodies against SARS-CoV-2 S glycoproteins comprising: (i) providing a surface coated with a SARS-CoV-2 S glycoprotein; (ii) exposing the surface to the biological sample; (iii) exposing the surface to a secondary antibody; and (iv) detecting the secondary antibody that is bound to the surface; wherein the biological sample contains antibodies that bind to the SARS-CoV-2 S glycoprotein if secondary antibody is detected.

ANTIVIRAL STRUCTURALLY-STAPLED SARS-CoV-2 PEPTIDE-CHOLESTEROL CONJUGATES AND USES THEREOF

Resumen de: US2025084128A1

Disclosed herein are cross-linked peptides either alone or conjugated to PEG(n)-cholesterol (or thiocholesterol) moieties useful for interfering with and inhibiting or preventing coronavirus infection (e.g., infection by SARS-CoV-2). Also disclosed are methods of treating and/or preventing a coronavirus infection (e.g., COVID-19.

INHIBITORS OF SARS-COV-2

Resumen de: US2025084091A1

Described herein are compounds and methods for the treatment of coronavirus infection. The compounds can function as an inhibitor of the main protease (Mpro) of coronaviruses. The compounds can include diphenylmethyl piperazine derivatives, diphenylmethyl piperidine derivatives, diphenylmethylidene piperidine derivatives, tricyclo9.4.0.03,8pentadeca-1(11),3(8),4,6,12,14-hexaen derivatives, tricyclo9.4.0.03,8pentadeca-1(11),3(8),4,6,9,12,14-heptaen derivatives, 6,11-dihydrobenzoc1benzoxepin derivatives, 6,11-dihydrobenzoc1benzothiepin derivatives, 5,5-dioxo-6,11-dihydrobenzoc1benzothiepin derivatives, and 6-oxo-5,11-dihydrobenzoc1benzazepin derivatives, as well as pharmaceutically acceptable salts, hydrates, and prodrugs thereof.

SMARTPHONE AND APP FOR PERSONAL PATHOGEN STATUS VERIFICATION AT POINT OF ENTRY INTO AN AREA OF CONGREGATION

Resumen de: US2025087037A1

A smartphone and app executed on the smartphone are used for personal pathogen status verifying that allows an entity to control access to an area of congregation (AOC) at one or more points of entry (POE). In one embodiment, the system may be used for the SARS-CoV-2 virus, but may be similarly used for other pathogens.

MEDICAL TEST RESULTS AND IDENTITY AUTHENTICATION SYSTEM AND METHOD

Resumen de: US2025087324A1

A system and method that enables users to provide authenticated medical records (e.g., vaccination records, viral anti-body test results, etc.) to a third-party (e.g., a venue) to gain access to the third-party is provided. In this way, the third party may confirm that the user is sufficiently immune to a particular disease (e.g., COVID-19) and may thereby minimize the threat of the user introducing the contagious disease to the third party. The system includes a biometric data recognition system that authenticates the identity of a user, a medical records acquisition system that acquires the medical records of the authenticated user, and a system for the displaying or otherwise providing the medical records to the third-party for review. The system also includes a system identification card that includes the user's contact information, alphanumeric characters associated with the user's driver's license number, medical records of the user, and other elements.

LATERAL FLOW ASSAY BY USING CARBOXYL LATEX BEADS AND BIOTIN-POLYSTREPTAVIDIN FOR THE DETECTION OF COVID-19 INFECTION AND DIAGNOSTIC KIT USING THE LATERAL FLOW ASSAY

Resumen de: US2025085278A1

The systems and methods herein are directed to carboxylated latex beads and biotin-polysterptavidin as a label material for fluorescence lateral flow assay (LFA) for the diagnosis of SARS-Cov-9 with increased sensitivity. The carboxylated latex and biotin-polystreptavidin instantly increases the fluorescence intensity and the resulting signal enhancement significantly increases sensitivity for analyte detection. The LFA can also be used for the detection of SARS-Cov-2 and as rapid testing kit of COVID-19. The LFA kit allows detection of nucleocapsid protein of SARS-Cov-2 as little as 0.1 ng/ml and as a point of care testing of COVID-19.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: US2024376178A1

The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2

Resumen de: AU2023265164A1

The disclosure provides, in various embodiments, polypeptides (

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: US2024376178A1

The invention relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the invention relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

COMPOSITIONS COMPRISING NANOPARTICLES FOR TARGETED DELIVERY AND METHODS OF USING THE SAME

Resumen de: WO2025049355A1

Disclosed herein are compositions comprising nanoparticles designed for CRISPR/Cas13 RNA targeting systems, specifically aimed at targeting poorly druggable, disease-driving genes in prostate cancer and COVID-19, and methods of use thereof.

T CELL BROAD BETACORONAVIRUS VACCINE

Resumen de: WO2025046130A2

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.

VIRAL STRAIN SEROLOGY ASSAYS

Resumen de: WO2025049305A1

The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.

PATHOGEN TEST DEVICE

Resumen de: US2025079025A1

A pathogen test device, including a center body to facilitate gripping thereof, a swab connected to at least a portion of a first end of the center body to absorb at least one fluid therein in response to contact with the at least one fluid, a testing container detachably connected to at least a portion of a second end of the center body to store a testing liquid therein, and a test display disposed on at least a portion of the center body to display a test result identifying a presence of at least one of COVID-19, strep, and control in response to inserting the swab with the at least one fluid into the testing container.

RAPID TEST DEVICE FOR THE DETECTION OF SARS-COV-2 VIRUSES AND THE RELATIVE ANTIBODY PRODUCTION

Resumen de: US2025076294A1

A rapid test device for the detection of SARS-CoV-2 viruses and for the relative antibody production including a substrate of the lateral flow immunochromatographic assay divided into 5 regions: a first reception area to receive the biological sample (“Sample Deposition”); a second area where the first reaction takes place between an analyte and the molecule used for its specific identification (“Conjugation pad”); a third area where the signal amplification uses the addition of the gold nanoparticles (“Signal amplification”); a fourth test area (“Test line”) and a fifth control area (“Control Line”) in which a second and third immunoreaction takes place, providing a visual reading of the test result by a window and two results visible by a colored strip. The sample deposition area comprises a filter having porosity of about 200 nm-1 μm.

INHIBITORS OF SARS-COV-2

Resumen de: US2025074907A1

Described herein are compounds, and methods for the treatment of coronavirus infection.

CELL-PERMEANT INHIBITORS OF VIRAL CYSTEINE PROTEASES

Resumen de: US2025074938A1

Provided are protease inhibitor compounds that find use in treating or preventing coronavirus disease. In some embodiments, the coronavirus disease is COVID-19. Also provided are compositions and kits comprising the compounds, as well methods of using the compounds to treat or prevent coronavirus disease. Also provided are methods for reporting coronaviral protease inhibition.

MULTIPLEXED DIAGNOSTIC ASSAY DEVICE

Resumen de: WO2025049225A2

Diagnostic assay devices for detecting the presence of an analyte in a sample solution may comprise a microreactor configured to form a sample solution containing the analyte, flow the sample solution therethrough in a first direction to form an analyte-capture molecule complex, and transfer the sample solution to an absorbent strip pad configured to flow therethrough, in a second direction crossing the first direction, the sample solution including the analyte-capture molecule complex and indicate a presence of the analyte-capture molecule complex. In some embodiments the devices are configured to process a bioaerosol sample. In some embodiments the diagnostic assay devices may be multiplexed and may be used for detecting the presence of two or more analytes in a sample solution. The diagnostic devices may be used, for example, to identify the presence of one or more of SARS-Cov2, RSV, influenza A, influenza B or other pathogens in samples from patients.

A KIT AND AN ASSAY FOR ANALYSING THE PRESENCE OF NEUTRALIZING ANTIBODY AGAINST SARS-COV-2

Nº publicación: WO2025046629A1 06/03/2025

Solicitante:

PT JAWAHAR LAL NEHRU MEMORIAL MEDICAL COLLEGE [IN]
PAL JAGANNATH [IN]
INDIAN COUNCIL OF MEDICAL RES [IN]
PT. JAWAHAR LAL NEHRU MEMORIAL MEDICAL COLLEGE,
PAL, Jagannath,
INDIAN COUNCIL OF MEDICAL RESEARCH